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The protein chaperoning and ubiquitin–proteasome systems perform many homeostatic functions within cells involving protein folding,
transport and degradation. Of paramount importance is ridding cells of mutant or post-translationally modified proteins that otherwise tend to
aggregate into insoluble complexes and form inclusions. Such inclusions are characteristic of many neurodegenerative diseases and implicate
protein misfolding and aggregation as common aspects of pathogenesis. In the most common familial form of ALS, mutations in SOD1 promote
misfolding of the protein and target it for degradation by proteasomes. Although proteasomes can degrade the mutant proteins efficiently, altered
solubility and aggregation of mutant SOD1 are features of the disease and occur most prominently in the most vulnerable cells and tissues. Indeed,
lumbar spinal cord of mutant SOD1 transgenic mice show early reduction in their capacity for protein chaperoning and proteasome-mediated
hydrolysis of substrates, and motor neurons are particularly vulnerable to aggregation of mutant SOD1. A high threshold for upregulating key
pathways in response to the stress of added substrate load may contribute to this vulnerability. The broad spectrum neuroprotective capability and
efficacy of some chaperone-based therapies in preclinical models makes these pathways attractive as targets for therapy in ALS, as well as other
neurodegenerative diseases. A better understanding of the mechanisms governing the regulation of protein chaperones and UPS components
would facilitate development of treatments that upregulate these pathways in a coordinated manner in neural tissue without long term toxicity.
© 2006 Elsevier B.V. All rights reserved.Keywords: Heat shock protein; Ubiquitin–proteasome system; Stress response; Heat shock response; SOD1; Amyotrophic lateral sclerosis; Preferential vulnerability;
Motor neuron1. Introduction
The 2004 Nobel Prize for Chemistry was awarded to Aaron
Ciechanover, Avram Hershko, and Irwin Rose for the discovery
of ubiquitin-mediated protein degradation. In his Nobel lecture,
Dr. Ciechanover stated: “With the multitude of substrates
targeted and processes involved, it is not surprising that
aberrations in the (ubiquitin–proteasome) pathway have been
implicated in the pathogenesis of many diseases, among them
certain malignancies, neurodegeneration, and disorders of the
immune and inflammatory system” [1]. This review sum-
marizes the current state of knowledge about the role of
proteasome-mediated degradation in the pathogenesis of
amyotrophic lateral sclerosis (ALS) and how impairment of
the ubiquitin–proteasome system (UPS) might relate to
inadequate stress responses in the affected neural cells. The⁎ Corresponding author. Tel.: +1 514 398 8509; fax: +1 514 398 1509.
E-mail address: heather.durham@mcgill.ca (H.D. Durham).
0925-4439/$ - see front matter © 2006 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2006.06.006UPS performs many homeostatic functions within cells
including nascent protein folding, transport and degradation
of proteins, signal transduction, cell growth and differentiation,
and control of apoptotic pathways. The proteasome is also the
major route for catabolizing misfolded proteins, preventing
them from aggregating into insoluble complexes. Protein
chaperones facilitate the restoration of functional protein
conformation or target misfolded proteins for degradation.
Thus, therapies that promote degradation of abnormal proteins
may have broad applicability in neurodegenerative diseases.
2. Protein misfolding in ALS
Many neurodegenerative disorders, including ALS, have in
common the sequestration of aberrant proteins into inclusions.
The identity of the constituent proteins and morphology of the
inclusions are pathognomonic of the disease. Proteins within
these inclusions often are ubiquitinated, and protein chaperones
and proteasomal subunits also may be sequestered [2–5]. Most
1039E. Kabashi, H.D. Durham / Biochimica et Biophysica Acta 1762 (2006) 1038–1050investigations of the role of the UPS in ALS have been
conducted using experimental models of the most common
familial form of ALS due to dominantly inherited mutations in
Cu/Zn-superoxide dismutase (SOD1) [6]. Inclusions containing
mutant SOD1 are found in motor neurons and sometimes
surrounding astrocytes of patients [7,8] and transgenic rodent
models [9,10], as well as in primary cultured motor neurons
expressing several different SOD1 mutants [11].
Whereas SOD1WT is for the most part a soluble enzyme,
disease-causing mutant proteins can be isolated in three
different biochemical states: soluble in nonionic detergent,
nonionic detergent-insoluble/SDS-soluble (up to 10%), and
SDS-insoluble polymers (less than 0.5%) [12–14]. Large
aggregates can be trapped by passing homogenate through
filter traps [14] and visualized as inclusions by immunohisto-
chemical labeling of tissue sections or transfected cells
[2,9,14,15]. In transgenic mice, the amount of insoluble and
high molecular weight mutant SOD1 is highest in tissue most
vulnerable to disease, suggesting that cells in these regions
process the mutant protein differently or inefficiently
[12,14,16,17]. Similarly, the propensity of mutant SOD1 to
form aggregates visible by microscopy depends on the cell type.
The preferential vulnerability of motor neurons manifests in
culture, mutant SOD1 forming inclusions in motor neurons of
spinal cord cultures following gene transfer, but not in dorsal
root ganglion or hippocampal neurons [11]. In various cell lines,
treatment with proteasomal inhibitors [12] promotes the
formation of inclusion bodies. Even mutant SOD1 that is
immunolabeled diffusely may be in the form of small oligomers
rather than the normal dimeric structure of SOD1WT [18],
consistent with a significant fraction of the protein being
detergent-insoluble even in the absence of distinct inclusions
[13].
Whereas there is evidence that inclusions may protect cells
from accumulated misfolded protein rather than being inher-
ently toxic, they do reflect failure of the proteolytic system to rid
cells of potentially harmful proteins [19]. In the case of mutant
SOD1, there are many studies in which inclusions served as a
marker of toxicity, although this by no means demonstrates they
are the cause of toxicity: the load of protein aggregates
correlates with motor neuron dysfunction in a transgenic mouse
model [17]; cultured motor neurons with inclusions develop
DNA fragmentation and chromatin condensation [11]; loss of
viability correlates with formation of mutant SOD1 inclusions
[11,12,18,20], and treatments that reduced formation of
inclusions prolonged viability of mutant SOD1-expressing
motor neurons [11,21] and Neuro-2A cells [22]. On the other
hand, survival of differentiated PC12 cells transduced with
mutant SOD1-YFP adenoviral vectors did not correlate with the
number of inclusions (however, inclusions of SOD1WT also
were observed in the study) [23], and targeting mutant SOD1 to
mitochondria induced cell death in the absence of cytoplasmic
inclusions, although oligomerization of mutant SOD1 in
mitochondria was not excluded [24]. This is a complex issue
that is influenced by the experimental paradigm (e.g., culture
versus animal models, tagged versus untagged constructs, stable
versus transient expression, exposure to additional stresses).Application of more sensitive techniques to resolve smaller
oligomeric forms of mutant protein in cells is needed, as these
are the species considered most likely to be toxic [25].
Evidence points to a “toxic gain of function” conferring
disease properties, with conformational abnormalities as the
common property. Over 100 mutations in SOD1 cause disease,
but have variable effects on enzymatic activity, and over-
expression of SOD1WT failed to cause ALS-like disease
[26,27]. Mutant SOD1 proteins, are catabolized by the
proteasome in cells [12,28–30], and recombinant SOD1
mutants are good substrate for the 20S proteasome in vitro,
particularly as metal deficient monomers lacking the intrasu-
bunit disulfide bond [31].
Studies of recombinant proteins in vitro or transfected
cultured cells subjected to oxidizing conditions show that dimer
destabilization (SOD1 functions as a homodimer) and poly-
merization of monomeric SOD1 are promoted by disease-
causing mutations, demetallation, disulphide reduction, and
oxidative modifications [32–47].Whereas these modifications
alter solubility and promote aggregation in vitro, it is not known
if the conformational alteration conferred by the mutation is
sufficient to cause proteotoxicity in vivo or if other post-
translational modifications contribute. In vivo, the major
conformational changes of SOD1 in affected tissues reported
are oxidation, protein nitration and 4-hydroxy-2-nonenal (HNE)
modifications of amino acids [48–51]. Regardless, chaperoning
and clearance of mutant SOD1 from the cell would prevent both
toxicity and formation of inclusions and cells that accomplish
this efficiently will be less vulnerable than those with less robust
protein chaperoning and proteasomal capacity.
3. The role of the ubiquitin–proteasome system in protein
turnover
Proteasomes are barrel-shaped protein complexes in the
cytoplasm and nucleus responsible for degrading most non-
vesicular proteins including short-lived regulatory molecules,
damaged (oxidized, glycated, nitrated, etc.), incompletely
translated, and mutant proteins in cells [3,52]. The ubiquitin–
proteasome system works in partnership with molecular
chaperones, highly conserved families of proteins important
for protein folding and transport. Various forms of cellular stress
can promote conformational changes that can alter the function
of a protein and promote aggregation with like or other proteins
[53]. Misfolding and aggregation are facilitated by molecular
crowding in the intracellular milieu [54]. Chaperones aid
partially folded or unfolded polypeptides to revert to their
functional conformation, preventing their interaction with
inappropriate partners and aggregation [55]. They are also
involved in various cellular processes including nascent folding,
transport and degradation of proteins, as well as signal
transduction, cell growth and differentiation, and preventing
apoptosis [56,57]. The most studied chaperones are the
constitutively expressed heat shock cognate proteins (HSCs)
as well as stress-inducible heat shock proteins (HSPs) [e,g.,
Hsp70(68,72,73), 40, 60, 90 and 110; the small HSPs: heme
oxygenase, ubiquitin, Hsp25/27, αB-crystallin; the glucose
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refolding or targeting abnormal proteins to the proteasome for
degradation. HSPs are induced in response to a variety of
stressful conditions (hyperthermia, oxidative stress, ischemia,
calcium ionophore, trauma, exposure to toxic chemicals, mutant
proteins, etc), a process termed the heat shock response. Cells
that can mount a robust heat shock response are better
positioned to survive the initial and subsequent insults. Fig. 1
summarizes the major pathways by which HSPs and protea-
somes regulate protein degradation in cells.Fig. 1. The role of protein chaperones and the ubiquitin–proteasome system (UPS) in
chaperones to prevent inappropriate protein–protein interactions and assist nascent p
errors, genetic mutation or post-translational modifications promote misfolding of
interactions with like or other proteins. These protein aggregates have reduced solubi
by recognizing hydrophobic domains of misfolded proteins and sequestering them t
process) or targeted to the proteasome for degradation. Proteasomes also degrade a
increases the substrate load of cytosolic HSPs and proteasomes. Neurotransmission a
of glutamate receptors at the cell membrane, but glutamatergic neurotransmission pro
maintain a balance between the levels of HSPs and UPS components and the substra
regulated by a negative feedback system whereby the major transcription factor cont
binding to a Hsp90 chaperone complex. When misfolded proteins compete for these c
elements (HSE) of heat shock genes. DNA-binding is not sufficient to initiate tr
phosphorylation and possibly dissociation of inhibitory proteins. Neurons, motor n
compromise their response to disease-related stresses. The major pathway identified i
elements (ARE) involving the Nrf2–Keap1 pathway that also controls transcripti
cytoplasm by binding to Keap1, which also promotes its degradation by the UPS
translocation of Nrf2 to the nucleus and initiation of gene transcription. (For referen3.1. Targeting aberrant proteins to the proteasome for
degradation
Although HSPs have in common the ability to recognize and
sequester misfolded proteins, Hsp70 and Hsp40, with asso-
ciated proteins and ATP, can refold proteins to their functional
conformation [59,60]. If proteins cannot be refolded, they are
escorted to the proteasome for degradation. As a general
principle, proteins are targeted to the proteasome by poly-
ubiquitination, a process whereby ubiquitinating enzymesmaintaining protein quality control. During polypeptide synthesis, HSPs act as
roteins in taking on and maintaining their functional conformation. Translational
proteins, which can expose hydrophobic domains and lead to inappropriate
lity and tend to come together as insoluble inclusions. HSPs prevent aggregation
o be refolded (by Hsp70, Hsp40 and other co-chaperones in an ATP-dependent
bnormal proteins from the endoplasmic reticulum, and as such, ER stress also
lso depends upon proteasome function. Not only is the UPS involved in turnover
motes aggregation of mutant protein in a calcium-dependent manner. Cells that
te load will be better positioned to defend themselves. HSP gene transcription is
rolling heat shock gene transcription (Hsf1) is maintained in an inactive state by
haperones, Hsf1 can translocate to the nucleus and binds as a trimer to heat shock
anscription. Rather subsequent steps are required to activate Hsf1 including
eurons in particular, have a high threshold for activation of Hsf1, which can
n upregulation of proteasomal gene transcription is through antioxidant response
on of phase II antioxidant/detoxification enzymes. Nrf2 is sequestered in the
. Oxidative stress signals dissociation of the Nrf2/Keap1 complex, permitting
ces see text).
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ubiquitin molecules. Ubiquitin is adenylated and activated by
binding of E1 (ubiquitin activating enzyme) in an ATP-
dependent fashion, then transferred to an E2 ubiquitin
conjugating enzyme. Then, HECT domain or RING-finger
motif-containing E3 ligases mediate linkage of ubiquitin to
lysinyl side-chains of the substrates [61]. Whereas only one E1
mammalian gene exists, hundreds of E3 ligases provide a
degree of specificity to ubiquitination of thousands of protein
substrates. Polyubiquitination is facilitated by E4 enzymes,
including C-terminus of Hsp70-Interacting Protein (CHIP) [62].
CHIP shuttles misfolded proteins from Hsp70 to the UPS,
inhibiting Hsp70's refolding activity through N-terminal TPR
motifs and facilitating ubiquitination of substrate through its U-
box (ubiquitin-ligase) domain [63]. CHIP promotes degradation
of several disease-associated proteins including mutant SOD1
[64,65].
Linkage of at least four ubiquitins via lysine 48 targets the
substrates to the proteaseome; however, monoubiquitination, or
lysine 63-linked ubiquitin chains do not target proteasomal
degradation, but serve other functions including signaling,
endocytosis, vesicular transport, protein sorting and transcrip-
tional regulation [66]. The process of ubiquitination is
reversible by deubiquitinating (DUB) enzymes [67].
3.2. Proteasomal structure
The 26S proteasome is a complex of approximately 2.5 MDa
in size comprised of a 20S catalytic core and two regulatory
subunits that recognize and unfold substrates [52]. The 20S
proteasome is a cylindrical unit consisting of 28 subunits (14
gene products), arranged as four heptameric staggered rings.
The two outer rings contain the structural α−subunits (α1–α7),
while the two inner rings contain two copies of the β-subunits
(β1–β7), three of which (β1, β2 and β5) harbour the six active
sites [68]. β5 cleaves preferentially after hydrophobic residues
[chymotrypsin-like activity], β2 after basic residues [trypsin-
like activity], and β1 after acidic residues [caspase-like activity,
a.k.a. peptidyl-glutamyl peptide hydrolase (PGPH)]. Some of
the β subunits are transcribed as proforms and need to be
cleaved during the assembly process in order to be functional
[69]. The assembly of the mammalian 20S proteasome is not
well understood, but appears to be mediated by POMP or
protoassemblin and Hsc73 [70,71]. Recently, two chaperones,
PAC1 and PAC2, were identified that associate with proteasome
precursors and promote proteasomal maturation [72]. The 19S
is composed of 18 different subunits and is responsible for
recognizing ubiquitinated substrates, unfolding them and
chaperoning them towards the proteolytic cavity [73]. In
yeast, the molecular chaperone, Hsp90, plays an important
role in assembly of 20S and 19S complexes and maintenance of
the resulting 26S proteasome [74].
In addition to general protein degradation, a key function of
proteasomes is to generate peptides for antigen presentation by
MHC class I. The cytokines LPS, TNF-α, and/or IFN-γ induce
expression of three alternate catalytic subunits, β5i, β2i, β1i
and components of a different regulatory subunit, 11S, alsoknown as PA28 [75]. The inducible subunits replace the
constitutive counterparts forming another complex known as
the immunoproteasome [76].Various intermediate/hybrid sub-
types of proteasome also have been isolated including 20S core
alone [77], 20S associated with one 19S and one 11S subunit
[78–80] and 26S proteasomes with different β-subunits.
Difference in subunit composition correlates with different
hydrolytic activity, the initial cleavage site used and the peptide
products generated. Although ubiquitination is the major signal
for proteasomal degradation, the 20S proteasome is able to
break down proteins in the absence of regulatory particles,
particularly oxidatively damaged proteins [81].
3.3. Regulation of proteasome gene transcription
In comparison to regulation of immunoproteasome subunits,
the molecular mechanisms regulating constitutive and stress-
induced expression of proteasome subunits in mammalian cells
are less well understood. In yeast, coordinated regulation of
genes encoding components of the proteasomal and ubiquitin
systems is achieved through binding of the transcription factor
Rpn4 to a common proteasome-associated control element
(PACE) [82,83]. Rpn4 regulates proteasome gene expression
through a negative-feedback loop. The transcription factor is
itself a proteasomal substrate, accumulating when proteasome
levels are insufficient, and being quickly degraded when
activity is restored [83,84]. No homolog of Rpn4 or its DNA-
binding element has been identified in the mammalian genome.
However, indirect antioxidants stimulate transcription of
numerous genes encoding 20S, 19S and 11S proteasomal
subunits, in addition to antioxidant/detoxifying enzymes,
through the antioxidant response element (ARE), an action
dependent on the Keap1-Nrf2 signaling pathway [85,86]. The
transcription factor Nrf2 is negatively regulated by binding to
Keap1 in the cytoplasm [87,88], which also promotes its
degradation by the UPS. Thus, like Rpn4 in yeast, Nrf2 is
maintained at low levels under low stress conditions by
proteasomal degradation [89]. Upon exposure to electrophiles
generated by xenobiotic or physiological stress, Nrf2 is released
from Keap1, translocates to the nucleus and initiates transcrip-
tion of a variety of stress response genes including phase II
detoxifying enzymes and proteasomal subunits. Peroxisome
proliferators also increase expression of proteasome genes, but
independent of Nrf2 [90], indicating that proteasome levels can
be altered through multiple pathways. Recently, Zif268was
identified as a repressor of transcription of some proteasomal
subunits [91]. Although in yeast, the major heat shock
transcription factor (Hsf1) influences expression of ubiquitin–
proteasome subunits (ubiquitin, an E3 ligase, and a ubiquitin
conjugating enzyme) [92], Hsf1 does not appear to regulate
proteasome genes or activity in mammalian cells [93].
4. Methods of measuring proteasomal activity
Distinct catalytic activities have been assigned to each of the
three active β-subunits and can be measured in cell/tissue
homogenates using fluorogenic peptide substrates specifically
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PGPH/caspase-like (β1) activities [94–96]. This technique
measures the ability of proteasomes present in the tissue extract
to catabolize an additional substrate load (fluorogenic sub-
strates) and can be expressed relative to a housekeeping protein
in the sample (total proteasome activity) or to levels of specific
proteasome subunits (specific activity). Proteolytic activity of
both 20S core alone and 20S with regulatory particles attached
(26S) is measured. The relative contribution to total activity will
depend upon the abundance in the tissue and the method of
tissue preparation; i.e., whether 26S remains intact or 19S/11S
detach. Addition of glycerol and ATP to the buffer preserves the
interaction of 20S core with regulatory particles [97].
To obtain measures of proteasome activity in vivo, fluo-
rescent reporter proteins have been constructed. Kopito's group
coupled green fluorescent protein (GFP) to a short degron, CL1
[ACKNWFSSLSHFVIHL] (GFPu), which promotes its poly-
ubiquitination and degradation by the 26S proteasome [98].
Dantuma's group has constructed two different ubiquitin-tagged
GFP substrates. First, the ‘N-end rule’ substrate, Ub-R-GFP, in
which the N-terminal arginine of GFP is recognized by the E3
Ubr1 after cleavage by deubiquitinating enzymes. In the second
construct, UbG76V-GFP, an N-terminally linked ubiquitin serves
as the acceptor for polyubiquitination, but the G76V substitution
prevents de-ubiquitination, thereby promoting efficient degra-
dation [99,100]. All of these reporter proteins have short half-
lives because of their efficient degradation by the UPS and
accumulate when proteasome activity is inhibited; thus increase
in GFP fluorescence is a measure of reduced ubiquitin-
dependent proteasomal activity. Lines of mice carrying the
UbG76V-GFP [101] or GFP-CL1 (GFPdgn) [102] transgene have
been generated to provide a readout of proteasome function in
vivo. The ability to monitor proteasome function in individual
cells without lysing tissue is more meaningful than having a
measure of activity in homogenate. However, this in situmethod
is not completely straightforward. Only ubiquitin-dependent
proteolysis is monitored (i.e., 26S activity) and the GFP reporter
can itself aggregate and compromise chaperoning capacity if
expression levels are too high [103]. The other issue is that rather
high level inhibition of specific proteasome activity, as measured
by fluorogenic substrates in homogenates, is required to observe
substantial increase in GFP reporter fluorescence [99,101,104].
If such levels of inhibition represent a threshold of function that
is only compatible with life over the short term, the reporters
may only monitor end-stages of pathogenesis. On the other
hand, biochemical measures of proteasome activity do not
provide sufficient information on functional impairment or cell
type differences. A combined approach using both biochemical
and in situ techniques is more informative.
Native gel electrophoresis is useful to examine the subunit
composition of proteasomes. Separation of 20S, 26S, precursors
and unassembled subunits can be accomplished by the 2-D
Coomassie-Blue native gel method; tissue lysates are run in the
first dimension on Blue native gels, then strips are placed
horizontally over denaturing SDS-polyacrylamide gels for sepa-
ration of the complexes into subunits in the second dimension
[105]. The native gel electrophoresis method described byFinley and colleagues is enriched with ATP and glycerol and
favours retention of the 26S complex [97]. In gel activity assays
using fluorogenic substrates provides a crude determination of
the proteolytic activity in the tissue samples [97]. These are
powerful techniques to evaluate proteasome composition in
small tissue samples.
5. Proteasome activity and structure in ALS
Because treating cells expressing mutant SOD1, but not
wild-type (WT) SOD1, proteins with proteasomal inhibitors
promotes insolubility and accumulation of the mutant protein as
well as formation of microscopically visible inclusions, it would
be logical that proteasomal function would be compromised in
cells and tissues that exhibit inclusions without exposure to
inhibitors.
5.1. Interaction of mutant SOD1 with UPS components
Inclusions in spinal cord of several mutant SOD1 transgenic
mouse models often are labeled by antibodies to members of the
ubiquitin–proteasome pathway [2]. There is biochemical
evidence showing that mutant SOD1, but not WT is poly-
ubiquitinated both in neuronal and non-neuronal cells and is
subsequently degraded by the 26S proteasome [29,36]. Several
E3 ligases can poly-ubiquitinate mutant SOD1 in vitro. The E3
ligase, dorfin interacts with mutant SOD1 and its overexpres-
sion decreases mutant SOD1 toxicity [29]. Two other E3
ligases, CHIP and NEDL1 also can interact with and
ubiquitinate mutant SOD1 [65,106,107]. Using microfluoro-
metric imaging techniques, Matsumoto et al. showed stable
association of transfected β5i (LMP7) proteasomal subunits
with mutant SOD1 inclusions in differentiated PC12 cells [18].
Collectively, these data show that mutant SOD1, but not WT
SOD1 proteins are catabolized by the proteasome and that
biophysical species with altered solubility are precursors of
larger inclusions. Under most circumstances cells are capable of
handling mutant SOD1 proteins sufficiently to prevent them
from exerting toxicity and/or being sequestered into inclusions.
Even motor neurons develop and function into adulthood.
However, under circumstances of increased physiological or
environmental stress or compromise of protective mechanisms
with aging, the UPS may become overloaded and impaired.
5.2. Measures of proteasomal activity in cell and mouse models
of fALS
Several studies have measured total proteasomal enzyme
activity by hydrolysis of fluorogenic substrates in cell lines
transfected with mutant SOD1 with mixed results. Total
proteasomal activity was decreased [36,108,109], increased
[110,111] or unchanged [112]. Differences in physiological
properties of clonal cell lines, including ability to upregulate
proteasomes or other protective mechanisms may have
contributed to disparate measures of activity.
In our laboratory, total and specific proteasomal activities
were measured in homogenates of tissue from SOD1G93A and
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[16]. Both total and specific chymotrypsin-like, trypsin-like and
caspase-like activities were significantly reduced in lumbar
spinal cord of SOD1G93A transgenic mice, the tissue that is
ultimately most affected pathologically, but not in the remainder
of the spinal cord or in liver. Chymotrypsin-like activity was
significantly impaired as early as 45 days postnatal, with allFig. 2. Impairment of both specific proteasome activity and altered proteasomal subu
like, trypsin-like and caspase-like proteasomal activities were measured by hydrolys
SOD1G93A transgenic mice, SOD1WT transgenic mice and their nontransgenic litterm
days of age). Original data showing decrease in total and specific activities in lumbar s
In this figure, means for each of the three activities in transgenic tissues relative to
capacity. (A) Total proteasome activities (normalized to actin) and (B) specific prote
levels of 20S α are unchanged at early stages of decreased proteasome activities, imm
neurons relative to the surrounding neuropil at later stages. Shown is immunolabel
antibody specific to human SOD1 from Sigma-Aldrich. Similar data were published
20S α in homogenate of lumbar spinal cord of symptomatic SOD1G93A and nontrans
chymotrypsin-like activity) is markedly reduced (in parallel with decreased chymo
increased expression of β5i indicating a shift to immunoproteasomes in conco
immunoproteasome was previously reported by Kabashi et al. [16], Cheroni et al. [11
David Tayor and by Dr. Jeffrey Agar, currently at Brandeis University.three activities reduced by about 50% at day 75 [16]. The early
decline in chymotrypsin-like activity corresponds to a reduction
in 20S β5 subunits, but not 20S α, 19S or 11S subunits (Fig.
2A, B and D). Subsequently, 20S α levels also decreased
specifically in lumbar motor neurons (Fig. 2C), indicating that
general levels of proteasome are reduced in affected neurons
during the symptomatic phase of the disease [16,113]. Thesenits in lumbar spinal cord of SOD1G93A transgenic mice. (A,B) Chymotrypsin-
is of exogenous fluorogenic substrates in homogenates of lumbar spinal cord of
ates at 45 days postnatal, 75 days or at symptomatic phase (approximately 120
pinal cord but not thoracic spinal cord or liver is published in Kabashi et al. [16].
littermate were averaged to obtain a measure of overall proteasome hydrolytic
asome activities normalized to level of 20S α structural subunits. (C) Whereas
unolabeling of 20S α subunits was dramatically reduced, specifically in motor
ing with antibody to α subunits of the 20S proteasome core from Affiniti and
previously in Kabashi et al. [16], and Cheroni et al. [113]. (D) Overall levels of
genic littermates are similar, but the amount of 20S β5 subunit (associated with
trypsin-like activity and before gliosis [16]. This is partly compensated for by
rdance with the presence of activated microglia in the region. Increase in
3] and Puttaparthi et al. [114]. Data for Fig. 2 contributed by Edor Kabayashi and
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measurements on specific regions of spinal cord in disease
models rather than pooling homogenates of whole spinal cord.
Measures of proteasome activities in whole spinal cord
homogenate from mutant SOD1 mice are unchanged or
increased relative to controls [113,114] and Kabashi et al.
(unpublished data).
Astrocytosis and gliosis are prominent features of spinal cord
pathology in both ALS patients and transgenic mouse models
and are fulminant by symptomatic age (120 days in the high copy
number SOD1G93A mouse line). This is reflected in an increase
in inducible components (β5i and llS) of the immunoproteasome
in symptomatic mice, substituting for constitutive 20S β
subunits and 19S subunits [16,113,114] (Fig. 2D).
5.3. Relevance of proteasomal dysfunction to ALS pathogenesis
The above findings demonstrate compromise of proteasomal
catabolic capacity in vulnerable tissues in a transgenic mouse
model of familial ALS. However, how that relates to disease
pathogenesis in the mouse model and in familial and sporadic
ALS patients requires further work. Measures of proteasomal
activities in homogenates of lumbar spinal cord of SOD1G93A
mice are reduced early in the disease process, but the cell types
involved and the functional consequences remain to be
elucidated. Bendotti's group is attempting to answer this
question by crossing SOD1G93A mice with UbG76V-GFP
transgenic mice. As discussed above, a caveat of the GFP
reporters of proteasomal function is that significant loss of
activity may be required before GFP accumulates to readily
visible levels ([99,104] and how long various spinal cord cells
live with this level of functional impairment is not known.
Studies in cell culture also support a significant role for
proteasome dysfunction in mutant SOD1 toxicity. Formation of
mutant SOD1-containing inclusions correlates with cell death in
primary cultured motor neurons [11]. Aggregation and toxicity
of mutant SOD1 are promoted by treating cells with proteasome
inhibitors [12,29,30]. In time lapse studies in PC12 cells, levels
of mutant SOD1 and a ubiquitin-GFP reporter of proteasome
activity increased before inclusions formed [18]. These events
correlated with subsequent cell death. On the other hand,
proteasome inhibitors increased the number of aggregates
formed but not cell death in PC12 cells expressing mutant and
wild type SOD1-YFP constructs [23]. Also, motor neurons in
organotypic spinal cord cultures prepared from SOD1G93A mice
did not show a preferential vulnerability to proteasome inhibitors
compared to those in cultures from non-transgenic mice [115].
Another issue is the mechanism underlying reduced protea-
some activity in lumbar spinal cord of SOD1G93A mice. The
early decrease in chymotrypsin-like activity appears too great to
be explained only by substitution of immunoproteasome for
constitutive proteasome or by changes in the cell type
composition of the tissue because of increased presence of
activated microglia and astrocytes, although these events do
occur in late pre-symptomatic and symptomatic stages [16].
Reduction in 20S β subunits without decrease in α subunits is
puzzling considering the proteasome ring structure. Preliminarydata from our laboratory show no significant reduction in tissue
mRNA levels or an increase in unassembled α subunits. Other
possibilities being explored are post-translational modification
of proteasomal proteins or substitution of other subunits.
Depletion of proteasomes by sequestion in inclusions or
choking of the proteasome by inclusions are unlikely mechan-
isms or [104].
Why does proteasomal impairment occur preferentially in
the most vulnerable tissue (lumbar spinal cord), but not more
generally? Although activities of proteasomes in spinal cord
may be relatively low compared to other tissues [30],
proteasome levels are normally high in motor neurons relative
to the surrounding neuropil [16,116] (Fig. 2C). The high level
expression of proteasomes and the high sensitivity of motor
neurons to proteasome inhibitors [36] would indicate that these
cells normally have a large substrate load. Part of this may be
due to neurotransmitter input because blocking AMPA
glutamate receptors both prolongs viability of cultured motor
neurons expressing mutant SOD1 and reduces formation of
inclusions [117]. Molecular crowding [54] or an intracellular
milieu favoring hydrophobic conformations of mutant SOD1 or
other proteins could also contribute [45].
How could impaired proteasome function contribute to
disease pathogenesis? Apoptosis is promoted by accumulation
of abnormal proteins and through depletion of HSPs that have
direct inhibitory effects on apoptotic pathways in addition to
their protein chaperoning activity [3]. The proteasome is the
major pathway for degradation of transcription factors and other
short-lived regulatory proteins, thus proteasomal inhibition
could alter transcription of multiple gene families including
those that promote cell death [118]. Another important function
of proteasomes is degrading misfolded proteins shuttled into the
cytoplasim from the endoplasmic reticulum (ER). ER stress
results from disturbance of ER calcium homeostasis or an
imbalance in the amount of misfolded protein and ER
chaperoning capacity; both ER and Golgi networks are
disrupted in ALS and experimental models of mutant SOD1,
implicating multiple compartments in failure of protein quality
control [119]. Proteasome inhibitors also disrupt mitochondrial
homeostasis [120,121]. Motor neurons in ALS patients and in
SOD1G93A and SOD1G37R transgenic mice do exhibit mito-
chondrial abnormalities [122] and the relationship between
mitochondrial and proteasomal dysfunction in ALS deserves
investigation.
5.4. Is the UPS a therapeutic target for ALS?
Either an increased generation of misfolded proteins or
decreased rate of hydrolysis could cause accumulation of
aggregation-prone or toxic proteins. Although increasing
proteolytic capacity would seem to be a rational approach,
inappropriate increase in proteasome activity could have
negative consequences. A clinical trial of recombinant human
ciliary neurotrophic factor (CNTF) in ALS patients was halted
because of dramatic loss of lean body mass [123]. CNTF
reportedly increases 20S proteasome mRNA and proteolytic
activity [124]. A kinder gentler way of assisting cells to cope
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Keap1-Nrf2 pathway whereby genes encoding multiple protec-
tive phase II antioxidant enzymes as well as proteasomal
subunits are coregulated through ARE. Such treatments might
also boost the antioxidant capacity of motor neurons, which
normally have low levels of reduced glutathione [125].
Interestingly, Nrf2 mRNAwas reduced in spinal motor neurons
of two fALS cases [126] Activation of Nrf2 in astrocytes can
indirectly protect neurons, including motor neurons [127,128].
That dietary factors stimulate these pathways has implications
for prevention as well as treatment [129].
6. Role of Protein Chaperones in ALS
6.1. Reduced protein chaperoning activity
Protein chaperones also play major roles in maintaining
protein quality control, working in complementary fashion
with antioxidant enzymes and proteasomes. The capacity for
both proteasomal protein degradation and protein chaperoning
are preferentially reduced in lumbar spinal cord of mutant
SOD1 transgenic mice, but not in tissues resistant to disease.
In two lines of mutant SOD1 transgenic mice (SOD1G93A and
SOD1G85R), chaperoning capacity was reduced in the lumbar
region of the spinal cord prior to the onset of symptoms
[21,130]. Why chaperoning activity is diminished is not
known, but logically would involve increased load of
misfolded proteins without increased levels of HSPs/HSCs to
maintain chaperoning function. The following evidence
supports direct interaction: Hsp70 was detected in the
insoluble fraction of spinal cord from SOD1G93A, but not
SOD1WT, transgenic mice and in spinal cord cultures prepared
from E13 SOD1G93A mice [13]. Similarly, the small HSPs
Hsp25 and αB-crystallin cofractionated with mutant SOD1 in
a transgenic mouse expressing SOD1 with the four copper-
coordinating histidines mutated [131]. This could result from
association with SOD1 or other misfolded proteins. Post-
translational modification of Hsp70 by HNE has also been
reported in these mice and could affect its chaperoning activity
or solubility [50]. Also, HNE-modified proteins are potent
inhibitors of the proteasome complex [132]. Direct association
of HSPs with mutant SOD1 is indicated by presence of Hsc70
in inclusion bodies in spinal cord of G93A and G85R SOD1
transgenic mice [2] and by transient association of Hsp70 with
mutant SOD1 inclusions in transfected cells [18]. Urushitani et
al. reported transient association of Hsp/Hsc70 with SOD1 and
CHIP [65]. However, Hsp70 was not detected in inclusion
bodies from mutant SOD1 transgenic mice and was rare in
ALS patients [2,133].
6.2. Is increasing levels of HSPs protective in models of fALS?
Over-expression of Hsp70 in cultured motor neurons
significantly decreased mutant SOD1 toxicity [21], although
this chaperone alone did not significantly affect disease in
transgenic mice [134]. However, upregulation of multiple
chaperones is more likely to have therapeutic benefit. AHsp70 and Hsp27 were more protective in combination than
individually in dorsal root ganglion neurons transduced to
express mutant SOD1 [135]. Arimoclomol, a coinducer of heat
shock gene transcription, improved hind limb muscle function,
delayed motor neuron death, and led to a 22% increase in
lifespan of SOD1G93A transgenic mice [136]. In our primary
culture model of fALS, co-expression of a constitutively active
form of the major heat shock transcription factor, Hsf1, or
treatment with geldanamycin (also known to activate Hsf1)
dramatically induced expression of Hsp70 and Hsp40 and was
highly protective [133,137].
Despite the protective properties of HSPs, motor neurons
have a high threshold for inducing a heat shock response to
various stressors, including heat shock [133,138]. Nonster-
oidal anti-inflammatory drugs (salicylate, cyclo-oxygenase 2
inhibitors), which increase HSP expression by increasing
Hsf1 binding to DNA in response to stress, are effective
inducers of Hsp70 in cultured astrocytes, but not in motor
neurons in either the absence or presence of heat shock or
disease-related stressors [139]. Similarly, in mutant SOD1
transgenic mice, HSPs are unchanged or decreased in motor
neurons, but small HSPs (Hsp25 and αB-crystallin) are
upregulated in reactive astrocytes [131,133,140–142].
Although upregulation of small HSPs is characteristic of
reactive glia in mice, this was not observed in spinal cord of
ALS patients [133]. Understanding the mechanisms whereby
some cells upregulate HSPs in response to stress and others
don’t will aid in development of compounds effective in
neurodegenerative disease.
6.3. Regulation of HSP gene transcription
Eukaryotic expression of HSPs is mediated by binding and
activation of heat shock transcription factors (HSF) to heat
shock elements (HSEs) on HSP promoters [143–145]. Envir-
onmental and physiological stresses activate transcription of
HSP genes in mammals largely through Hsf1 [143]. In the most
accepted model, Hsf1 is sequestered in the cytoplasm bound to a
multichaperone complex including Hsp90 and Hsp70. Upon
stress, misfolded proteins compete for HSPs, releasing Hsf1 to
translocate to the nucleus and bind as a trimer to HSE in HSP
promoters. Subsequent steps are required to activate Hsf1
including phosphoryation of key residues in its regulatory
domain, and release of inhibitory chaperone complexes
[143,144,146]. Redox-dependent activation of Hsf1 through
oxidation of cysteine residues could also promote trimerization
and DNA binding [147].
Another HSF, Hsf2, is an important developmental
regulator [148], but might also be involved in the heat shock
response in association with Hsf1 [149]. Like many transcrip-
tion factors, Hsf2 is a proteasomal substrate and accumulates
with proteasome inhibition [150]. Treatment of cultured motor
neurons with proteasome inhibitors causes both nuclear
accumulation of Hsf2 and expression of Hsp70 [133]. It is
not clear to what extent Hsf2 is responsible, but this pathway
is potentially an alternative therapeutic target to enhance HSP
production.
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Matching levels of protein chaperones and the UPS to the
substrate demand in times of stress is highly important to
maintain homeostasis. Some cells, some tissues and some
individuals do that better than others [151]. In models of familial
ALS, both proteasome and chaperoning function are abnormal in
the tissue most vulnerable to the disease process. Whether this is
the case in familial and sporadic ALS patients is under
investigation. The broad spectrum capability for cytoprotection
makes these pathways attractive as targets for therapy in ALS,
and other neurodegenerative diseases. However, HSPs also can
be toxic [57] and the mechanisms governing their regulation at
the transcriptional and post-transcriptional levels are highly
complex. A better understanding of these mechanisms, devel-
opment of treatments that upregulate these pathways in a
coordinated manner, and use of preclinical test models that
evaluate effectiveness of therapeutics in models that represent
the cell types affected in the disease are encouraged.
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